Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleCommentary

Data Generated by Quantitative LC-MS Proteomics Are Only the Start and Not the Endpoint: Optimization of QconCAT-Based Measurement of Hepatic UDP-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J Novak, Zubida M Al-Majdoub, Theunis C Goosen, Amin Rostami-Hodjegan and Jill Barber
Drug Metabolism and Disposition March 26, 2018, dmd.117.079475; DOI: https://doi.org/10.1124/dmd.117.079475
Brahim Achour
1 University of Manchester;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alyssa Dantonio
2 Pfizer Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Niosi
2 Pfizer Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan J Novak
2 Pfizer Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zubida M Al-Majdoub
1 University of Manchester;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theunis C Goosen
2 Pfizer Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin Rostami-Hodjegan
1 University of Manchester;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill Barber
1 University of Manchester;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jill.barber@manchester.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Quantitative proteomic methods require optimization at several stages, including sample preparation, LC-MS/MS and data analysis, with the final analysis stage being less widely appreciated by end-users. Achour et al. (2017b) previously reported measurement of eight uridine-5'-diphospho-glucuronosyltransferases (UGT) generated by two laboratories [using stable isotope-labeled (SIL) peptides or quantitative concatemer (QconCAT)], which reflected significant disparity between proteomic methods. Initial analysis of QconCAT data showed lack of correlation with catalytic activity for several UGTs (1A4, 1A6, 1A9, 2B15) and moderate correlations for UGTs 1A1, 1A3 and 2B7 (Rs=0.40-0.79, p<0.05; R2=0.30); good correlations were demonstrated between cytochrome P450 activities and abundances measured in the same experiments. Consequently, a systematic review of data analysis, starting from unprocessed LC-MS/MS data, was undertaken, with the aim of improving accuracy, defined by correlation against activity. Three main criteria were found to be important: choice of monitored peptides and fragments, correction for isotope-label incorporation, and abundance normalization using fractional protein mass. Upon optimization, abundance-activity correlations improved significantly for six UGTs (Rs=0.53-0.87, p<0.01; R2=0.48-0.73); UGT1A9 showed moderate correlation (Rs=0.47, p=0.02; R2=0.34). No spurious abundance-activity relationships were identified. However, methods remained sub-optimal for UGT1A3 and UGT1A9; here hydrophobicity of standard peptides is believed to be limiting. This commentary provides a detailed data analysis strategy and indicates, using examples, the significance of systematic data processing following acquisition. The proposed strategy offers significant improvement on existing guidelines applicable to clinically-relevant proteins quantified using QconCAT

  • drug development/discovery
  • enzyme kinetics
  • glucuronidation/UDP-glucuronyltransferases/UGT
  • in vitro-in vivo prediction (IVIVE)
  • proteomics
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (10)
Drug Metabolism and Disposition
Vol. 51, Issue 10
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Data Generated by Quantitative LC-MS Proteomics Are Only the Start and Not the Endpoint: Optimization of QconCAT-Based Measurement of Hepatic UDP-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCommentary

Data Generated by Quantitative LC-MS Proteomics Are Only the Start and Not the Endpoint: Optimization of QconCAT-Based Measurement of Hepatic UDP-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J Novak, Zubida M Al-Majdoub, Theunis C Goosen, Amin Rostami-Hodjegan and Jill Barber
Drug Metabolism and Disposition March 26, 2018, dmd.117.079475; DOI: https://doi.org/10.1124/dmd.117.079475

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCommentary

Data Generated by Quantitative LC-MS Proteomics Are Only the Start and Not the Endpoint: Optimization of QconCAT-Based Measurement of Hepatic UDP-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J Novak, Zubida M Al-Majdoub, Theunis C Goosen, Amin Rostami-Hodjegan and Jill Barber
Drug Metabolism and Disposition March 26, 2018, dmd.117.079475; DOI: https://doi.org/10.1124/dmd.117.079475
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Kirchhoff's Laws and the well-stirred model
  • kcat Assessment of UGT Enzymes across Different Organs
  • Clearance Models: The Case for Status Quo
Show more Commentary

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics